anthera logo

Open-label extension study

 

Study Summary:

The primary objective of this study is to evaluate the long-term safety of A-623 in subjects with SLE.

For latest updates please go to clinicaltrials.gov

 

Status:

Completed

 

Systemic Lupus Erythematosus Publications:

Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et. al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953–62.
doi:10.7326/0003-4819-142-12 Part 1-200506210-00004

Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, and Grober J. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811–19.
doi: 10.1136/ard.2006.065763

Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550–58.
DOI: 10.1056/NEJMoa051135


Disclaimer: All information provided on the official Anthera Pharmaceuticals, Inc. (Anthera) website is provided for information purposes only and is subject to change without prior notice. Although every reasonable effort is made to present current and accurate information, Anthera makes no guarantees of any kind.

© Anthera Pharmaceuticals, Inc., All Rights Reserved.